FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

Infants with KMT2A ‐rearranged acute lymphoblastic leukemia ( KMT2A -r ALL) have a poor prognosis. KMT2A -r ALL overexpresses FLT3, and the FLT3 inhibitor (FLT3i) lestaurtinib potentiates chemotherapy‐induced cytotoxicity in preclinical models. Children’s Oncology Group (COG) AALL0631 tested whether...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Leukemia Ročník 35; číslo 5; s. 1279 - 1290
Hlavní autori:	Brown, Patrick A., Kairalla, John A., Hilden, Joanne M., Dreyer, ZoAnn E., Carroll, Andrew J., Heerema, Nyla A., Wang, Cindy, Devidas, Meenakshi, Gore, Lia, Salzer, Wanda L., Winick, Naomi J., Carroll, William L., Raetz, Elizabeth A., Borowitz, Michael J., Small, Donald, Loh, Mignon L., Hunger, Stephen P.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 01.05.2021 Nature Publishing Group
Predmet:	631/67/1059/602 631/67/1990/283/2125 82 96/95 Acute lymphoblastic leukemia Acute lymphocytic leukemia Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer in children Cancer Research Carbazoles - therapeutic use Chemotherapy Children Critical Care Medicine Cytotoxicity Drug therapy Female fms-Like Tyrosine Kinase 3 - antagonists & inhibitors Furans Genetic aspects Hematology Histone-Lysine N-Methyltransferase - metabolism Humans Infant Infants Inhibitors Intensive Internal Medicine Leukemia Lymphatic leukemia Male Medical prognosis Medicine Medicine & Public Health Methods Myeloid-Lymphoid Leukemia Protein - metabolism Oncology Pediatric research Pharmacodynamics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Protein Kinase Inhibitors - therapeutic use Toxicity United States
ISSN:	0887-6924, 1476-5551, 1476-5551
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!